Rare Disease Biotech Mereo BioPharma Pulls $70M US IPO
Mereo BioPharma Group PLC, a biopharmaceutical company focused on rare diseases, on Thursday formally withdrew plans to list on the Nasdaq, a little less than a year after the London-based company...To view the full article, register now.
Already a subscriber? Click here to view full article